Clinical trials

Woman tests blood glucose level
#AdipoPharma #Biotech #Clinical trials #France #Funding #Type 2 diabetes

Investments pave way for type 2 diabetes breakthrough 

French biotech AdipoPharma is developing a novel and promising type 2 diabetes drug, for which it has successfully secured the funding needed to begin Phase I clinical trials. The company expects to begin clinical trials in the US in mid-2025.     This funding will enable AdipoPharma to accelerate… Read More

#News

#Centessa Pharmaceuticals #Clinical trials #Narcolepsy #Neuroscience #Sleep disorders

Centessa initiates Phase II trial in patients with sleep/wake disorders 

Centessa Pharmaceuticals has initiated a Phase II trial of ORX750, an investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia.  ORX750 was designed using Nxera Pharma technology to directly… Read More

#News

Human liver
#Clinical trials #Liver cirrhosis #Liver disease #Metabolomics

Positive clinical results for liver cirrhosis  

EnteroBiotix has announced positive results from its Phase Ib IMPuLCE study evaluating EBX-102 in patients with liver cirrhosis.  EnteroBiotix’s first-in-human study of EBX-102 was a randomised, double-blind, placebo-controlled Phase Ib study of adult participants with stable liver cirrhosis. It was designed to evaluate the safety, tolerability, and… Read More

#News

Cancer tumour
#Cancer therapeutics #Clinical trials #Immunology #Society of Immunotherapy for Cancer (SITC) #Storm Therapeutics

New clinical data on first-in-class METTL3 inhibitor 

Storm Therapeutics has presented promising data from its Phase I clinical study evaluating its METTL3 RNA methyltransferase inhibitor, STC-15, at the Society of Immunotherapy for Cancer (SITC) 39)th Annual Meeting, held in Houston, US, from 6-10 November 2024.    The Phase I clinical study… Read More

#News

#Biotechnology #Clinical trials #Drug development #Fibrotic disease

Calluna Pharma advances lead candidate for fibrotic diseases 

Biotechnology company Calluna Pharma has completed a Phase I clinical study for its lead product candidate targeting inflammatory and fibrotic diseases.  The company’s lead candidate, CAL101, was shown to have a favorable safety, pharmacokinetic (PK) and immunogenicity profile in the Phase I study.  CAL101 is… Read More

#News

Diversity
#Clinical trials #Diversity #Drug development #Drug discovery #FDA #Inclusivity

Opinion: Are FDA plans enough to boost inclusivity within clinical trials?

DDW Editor Reece Armstrong examines whether recent FDA plans to boost diversity within clinical trials are enough to tackle the scale of the problem. In June this year, the US Food and Drug Administration (FDA) issued draft guidance designed to help boost the engagement of underrepresented communities within clinical trials.  … Read More

#Exclusive Content

Woman with painful shoulder
#Clinical trials #Drug development #Drug discovery #Phase I trial

Novel pain relief drug enters Phase I trials 

The first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist, which it is hoped will treat chronic pain without the potential for abuse.   The trial will include 90 healthy volunteers and aims to demonstrate a favourable safety and… Read More

#News

#Clinical trial design #Clinical trials #Drug development #Drug discovery

Is disclosure non-compliance harming drug development?

Ali Pashazadeh, Founder and CEO of Treehill Partners, explores how clinical trial disclosure non-compliance is placing major pressures on clinical development, biopharma investment, and patient access to life saving therapies. Clinical trial disclosure non-compliance is rarely discussed and often ignored as a problem in the drug development sector. It is,… Read More

#Exclusive Content

#Clinical trials #Drug delivery #Drug discovery #Patient centricity

Patient-centric clinical trials: Prescription for better health outcomes 

Kimberly Gentile​, Senior Vice President of Clinical Operations at Biohaven Pharmaceuticals, explores the importance of newer patient-centric clinical trial strategies that can help enable better outcomes.   Drug development is my passion. My 30-year career in the pharmaceutical industry has been spent on the frontline of clinical research. I love what… Read More

#Exclusive Content

Cancer cells
#Aprea Therapeutics #Cancer research #Clinical trials #Solid tumours #Tumour biology

Cancer therapy innovation to overcome traditional limitations 

DDW’s Megan Thomas interviews Dr Oren Gilad, President and CEO of Aprea Therapeutics, about the company’s targeted therapeutics that overcome the traditional issues associated with chemotherapy such as toxicity and tumour resistance.  MT: Can you provide an overview of Aprea Therapeutics’ approach to developing new cancer therapies and how it… Read More

#Cancer Research #Exclusive Content

Doctor prepares vaccine
#Clinical trials #Immunology / Virology & Vaccines #Marburg virus #Vaccine candidate #World Health Organization

Vaccine trials to start in response to Marburg virus outbreak

Rwanda will start clinical trials of experimental vaccines and treatments for Marburg virus in the next few weeks, its health minister announced following news of an outbreak in the country. Marburg virus disease is highly virulent and causes haemorrhagic fever, with a fatality ratio of up… Read More

#News #Trending News

Laboratory research
#Clinical trials #FDA #Funding #Orphan drugs #Rare disease

FDA awards grants to seven clinical trials for orphan products

The US Food and Drug Administration (FDA) has announced seven new clinical trial grants awarded under the Orphan Products Grants Program for clinical trials to address the unmet needs of people affected by rare diseases. In total, clinical researchers will receive approximately $17.2 million over the next four years. Newly… Read More

#News #Regulatory

Boy tests his blood sugar levels at home
#Clinical trials #Diabetes #Drug development #Drug discovery #Regulatory

Bridging the gap between islet allo-transplantation and regulatory reform

Dr Rita Bottino, Director of Islet Programs at Imagine Pharma, discusses the need for regulatory reform in islet allotransplantation for type 1 diabetes.   Islet allotransplantation – the transplantation of isolated pancreatic islets from a deceased donor to a living recipient with type 1 diabetes – has emerged as a promising therapy… Read More

#Exclusive Content

Vaccine
#Clinical trials #Drug development #Funding #Immunology / Virology & Vaccines #Respiratory #Vicebio

New financing and clinical trial for RSV/hMOV bivalent vaccine

Vicebio has announced a $100 million Series B financing, which will be used to develop next-generation vaccines for respiratory viruses.   The development will utilise Vicebio’s Molecular Clamp technology, discovered at The University of Queensland. The technology stabilises viral glycoproteins in their highly immunogenic ‘prefusion’ conformation, crucial for… Read More

#News

Cancer immunotherapy
#Cancer immunotherapy #Cancer research #Clinical trials #Immunotherapy #RNA #RNA modifying enzymes #Storm Therapeutics

Could RNA modifying enzymes boost response rates? 

Cancer immunotherapy has set new standards in cancer care, but many patients are still not responding. RNA modifying enzymes (RME) research could be a way to improve results. DDW’s Megan Thomas reflects on STORM Therapeutics’ approach for the future of this mechanism of action.   Turning points and catalysts March 2011… Read More

#Cancer Research #Exclusive Content #Opinion

Cancer metastasis
#Cancer therapeutics #Clinical trials #ESMO #Events #Oncology

The latest breakthroughs in cancer research

The European Society for Medical Oncology (ESMO) Congress 2024 took place in Barcelona, Spain, 13-17 September 2024, and featured some significant breakthroughs in cancer drug discovery. NIAGARA Phase III trial AstraZeneca presented positive results from its NIAGARA Phase III trial, a global study to evaluate the… Read More

#Cancer Research #News #Trending News